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A B S T R A C T
Gestational diabetes mellitus is a carbohydrate intolerance recognized in pregnancy. The objective of this study was to
determine the prevalence of gestational diabetes mellitus (GDM) of all deliveries at the University Hospital Rijeka, Cro-
atia (34 997 deliveries over 10-year period) using 2-hour 75 g oral glucose tolerant test and to evaluate the impact of
GDM on neonatal outcomes and mother’s health. Gestational diabetes was diagnosed in 55 of 128 pregnant women with
suspected glucose intolerance. Logistic regression analysis was used to examine the relationship between fasting plasma
glucose, age, family history, body mass index, maternal weight gain, neonatal weight, neonatal head diameter and Apgar
score in the gestational diabetes group and in the non-diabetes group. The results indicate that fasting plasma glucose
greater than 7.0 mmol/L and maternal overweight are strong predictors for GDM and macrosomia. There was no differ-
ence in the mode of delivery, and vitality and metabolic complications among the infants of all analyzed mothers. We con-
cluded that to prevent GDM as well as to reduce the rate of macrosomic infants good glycemic control should be initiated
as soon as possible. The 2-hour 75 g OGTT is worth enough to evaluate GDM. Women should be counseled and encour-
aged to lose weight before or at the beginning of the conception period.
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Introduction
Gestational diabetes mellitus (GDM) is a carbohydra-
te intolerance recognized in pregnancy1–3. This definition
also includes previously undiagnosed diabetes or impai-
red glucose tolerance (IGT). GDM is induced by maternal
insulin resistance and usually develops in the second tri-
mester of pregnancy4,5. The impaired insulin secretion
and insulin in-sensitivity also play an important role in
the GDM pathogenesis6,7. The development of GDM is
connected with serious implications on pregnancy, the
future health of the mother, and may also affect the
health of the fetus and the child8–11.
There is no firm consensus regarding the diagnostic
criteria for GDM12–14. Of the several criteria employed to
diagnose GDM in Europe, most have not been equally ap-
plied in pregnancy. The screening technique typically
used in the United States is an l-hour 50 g oral glucose
challenge test (GCT), with a subsequent 3-hour l00 g glu-
cose tolerance test (OGTT) for women whose GCT is positi-
ve15. In the attempt to standardize the diagnosis of GDM,
the WHO has proposed using a 2-hour 75 g OGTT6. In
GDM 1-hour glucose levels do not differ after 75 g or 100
g loads or after glucose measurement in capillary or ve-
nous plasma16. Some authors suggest a breakfast glucose
test as useful in identifying a high-risk population in
which clinic follow-up may be used safely17.
This study was conducted to determine the preva-
lence of GDM among women receiving regular prenatal
care at the Clinic of Obstetrics and Gynecology. We were
also interested in identifying the risk factors for GDM
development (age, maternal weight and weight gain,
body mass index, family history) and to determinate
their consequences on neonatal birth weigh and their re-
lationship with the newborn’s and mother’s outcomes.
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Subjects and Methods
Over the period of 10 years we have analyzed 140
pregnant women with hyperglycemia. Patients with fast-
ing plasma glucose (FPG) higher than 7.0 mmol/L (ve-
nous plasma) have been identified as hyperglycemic pa-
tients. The examination started with a family history of
diabetes mellitus or hypertension. The measurement
lasted 2 days. All pregnant women with hyperglycemia
were submitted to 2-hour 75 g OGTT from full venous
blood. Values of the test were analyzed using the WHO
criteria. All data analyzed were from women between
24–28 weeks of pregnancy. The weight of the pregnant
women was based on body mass index (BMI) before preg-
nancy and weight gain during pregnancy. The routine
biochemical and hematological blood analysis were per-
formed. Tocography and ultrasonic examination were
performed in all pregnant women. The condition of new-
born babies was estimated on the basis of birth weight,
neonatal head diameter and Apgar score at one and five
minutes.
All statistical analysis was done using the SAS System
package on Windows platform. Univariate analysis was
performed comparing the difference in all the variables
between the non-diabetes and gestational diabetes group.
The significance of difference was assessed by Wilcox on
rank-sum test for the continuous variables and by t-test
for the categorical variables. Logistic regression was per-
formed to find possible predictors of gestational diabetes
group. Probabilities of less than 0.05 were accepted as
significant.
Results
Of the 140 pregnant women examined for the diagno-
sis diabetes, 12 were on intense insulin therapy (8.6%),
and 128 had suspected glucose intolerance (91.4%). In
the group with suspected glucose intolerance a 2-hour 75
g OGTT was carried out. Glucose intolerance was con-
firmed in 55 (42.9%) while 73 of 128 women (57.1%) had
normal OGTT values.
The features of healthy and GDM patients were col-
lected (Table 1.) and the following variables were com-
pared between the two groups: fasting plasma glucose –
first day (FPG1), fasting plasma glucose – second day
(FPG2), age (A), family history (FH), body mass index
(BMI), maternal weight gain (MW), neonatal weight
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TABLE 1
GENERAL CHARACTERISTICS OF THE PATIENTS: NON DIABETES VERSUS GESTATIONAL DIABETES





A 32.20±5.87 29.99±5.56 0.0475
MW 15.86±3.49 12.78±5.33 < 0.001
BMI 29.29±5.16 24.77±2.68 < 0.001
FPG1 6.39±0.64 6.00±0.28 < 0.001
FPG2 6.49±0.63 6.16±0.44 0.0037
NHD 35.44±1.29 34.59±1.44 0.001
AS1 8.00±1.58 7.90±1.77 0.7278
AS5 8.95±1.31 8.67±1.31 0.1395
NW 4178.00±549.01 3563.70±513.98 < 0.001
N / % N / %
FH neg. 40 / 72,73 58 / 79.45 0.374
FH pos. 15 / 27.27 15 / 20.55
A – age, MW – maternal weight gain, BMI – body mass index, FPG1 – fasting plasma glucose – first day, FPG2 – fasting plasma glucose
– second day, NHD – neonatal head diameter, AS1 – apgar score after one minute, AS5 – apgar score after five minutes, NW – neonatal
weight, FH – family history
TABLE 2
SENSITIVITY, SPECIFICITY, POSITIVE PREDICTIVE VALUES, NEGATIVE PREDICTIVE VALUES AND DIAGNOSTIC EFFICIENCY AC-












Z1 –0.31008 87.27 83.56 20.00 10.29 85.16
Z2 –0.21428 81.82 84.93 19.64 13.89 83.59
Z3 –0.21922 81.82 84.93 19.64 13.89 83.59
(NW), neonatal head diameter (NHD), Apgar score after
the first minute (AS1) and Apgar score after the fifth
minute (AS5). Univariate analysis showed significant
difference in mean values of the two groups, for all the
variables except for AS1 and AS5. The patients from the
gestational diabetes group were slightly older than the
non-diabetes group (mean of 32.2 years in gestational
group vs. 30.0 years in non-diabetes group, p=0.0475).
Both FPG variables, as well as NHD and all three obesity
related variables (NW, MW and BMI), were on average
significantly higher in the gestational diabetes group.
Logistic regression was performed to identify which
variables in combination predicted GDM. We included all
potential predictive variables in the model and, using the
backward elimination stepwise approach, eliminated one
by one the variables that did not significantly contribute
to the prediction of gestational diabetes. The variables
were FPG1, FPG2, A, FH, BMI, NW, MW, NHD, AS1 and
AS5. After the elimination of the no significant variables,
a combination of four variables was found to be a signifi-
cant predictor in the model: FPG1, BMI, AS5 and NW.
The resulting model for the prediction of gestational dia-
betes mellitus was: Z1= –32.35 + 1.77 x FPG1 + 0.31 x
BMI + 0.47 x AS5 + 0.0023 x NW. Further, we con-
structed an additional model in which we included all the
resulting variables from the previous model, as well as
their interactions (FPG1 x AS5, FPG1 x NW, FPG1 x
BMI, AS5 x NW, AS5 x BMI, and NW x BMI). After the
elimination of no significant variables, just two of all the
variables remained in the model as significant predictors
of gestational diabetes: FPG1 x BMI and FPG1 x NW.
The resulting model was: Z2 = –15.40 + 0.05 x FPG1 x
BMI + 0.0003 x FPG1 x NW
Comparing the two models we observed that in the
second model (Z2) there was no ASB5 variable, so we ad-
ditionally tested the new model with variables FPG1,
BMI and NW. The resulting model was: Z3 = –28.34 +
1.96 x FPG1 + 0.31 x BMI + 0.002 x NW
The sensitivity, specificity and diagnostic accuracy of
these three models were also analyzed (Table 2.) Using
the receiver-operating curve (ROC) for all the models we
determined the threshold values maximizing the sensi-
tivity and specificity of each model.
Discussion
According to the records of the Clinic of Gynecology
and Obstetrics at the Clinical Hospital Center Rijeka,
only 0.034% pregnant women have type 1 diabetes melli-
tus. The incidence of type 1 diabetes mellitus in our re-
gion is 2.2% of the population18. The incidence of fasting
hyperglycemia among the total number of deliveries is
also small (0.36%, namely 128 cases). The threshold of
our fasting glycemic values is probably the reason for the
true »pathological hyperglycemia«. Nevertheless, the
threshold values for hyperglycemia estimation in preg-
nancy are not small, and they are more useful in identifi-
cation among the overall population in which further in-
vestigation may be necessary13.
We have been using 2-hour 75 g OGTT as a second
step to diagnose GDM for many years now. Usually the
prevalence of GDM reported in the literature is from 0.15
to 15%6,19,20. In a fasting hyperglycemia group we found
positive OGTT in 43% (55 of the 128 pregnant women),
which is 0.16% of total number of deliveries. As we mea-
sured FPG and obtained higher limit values with OGTT
as well, we considered that the FPG was sufficient in
evaluating GDM. Lowering the cut point of glycemia we
can increase sensitivity but decrease specificity. Decrea-
sing the limit values of OGTT could even result in over
diagnosis of GDM. Although it is open to discussion
which of the criteria are better to use – the WHO criteria
or the GDM diagnose criteria recommended by the Ame-
rican Diabetes Association, a uniformly standardized test
could be more useful in comparing the results of differ-
ent GDM studies.
We found that pregnant women with diabetes melli-
tus and GDM were overweight during pregnancy, and
some, before pregnancy as well. The maternal glucose
level increase in a 2-hour 75 g OGTT could be largely ex-
plained by an increasing BMI21. Overweight is probably
the reason for induction of GDM and consequently ma-
ternal insulin resistance or impaired insulin secretion or
insulin sensitivity5,7,22. The opinion that insulin secre-
tion is affected by gene mutation is not confirmed23.
Even moderate overweight status is a significant risk fac-
tor for obstetrical and fetal complication24,25. The au-
thors confirm that macrosomia is more frequent in preg-
nant overweight women26. To prevent some of the com-
plications it is necessary to decrease BMI, even before
pregnancy as well as during pregnancy, both with ade-
quate nutrition and exercise27,28.
Our opinion is that BMI is more predictive of macro-
somia than weight gain. However, weight gain between
pre-pregnancy and postpartum as well as insulin resis-
tance in late pregnancy can predict abnormalities of glu-
cose tolerance soon after delivery29.
We did not find any congenital malformation in new-
borns and it confirms the Jenssen et al. statement that
there is a weak association between congenital malfor-
mations and GDM30. According to the Apgar score there
was no difference between newborn babies in our study,
which is in accordance with some other findings31,32.
Our results indicate that overweight before and dur-
ing pregnancy together with a FPG greater than 7.0
mmol/L in the third trimester of pregnancy are strong
predictors for GDM, and to GDM-related complications.
The 2-hour 75 g OGTT is worth enough to confirm GDM.
The reduction in weight before and during pregnancy by
adequate nutrition and physical activity, as well as the
early detection and appropriate treatment of GDM are
representing crucial measures in appropriate treatment
of pregnancy in women at high risk for GDM develop-
ment.
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PREDIKTIVNI BILJEZI GESTACIJSKOG DIJABETESA
S A @ E T A K
Gestacijski dijabetes melitus (GDM) je intolerancija glukoze u trudno}i. Cilj studije je bio odrediti prevalenciju GDM
u ukupnom broju poroda Klini~kog bolni~kog centra Rijeka, Hrvatska, tijekom desetogodi{njeg razdoblja (ukupno 34
997 poroda) kori{tenjem dvosatnog testa optere}enja sa 75 g glukoze i procijeniti utjecaj GDM na zdravstveni status
~eda i majke. GDM je potvr|en u 55 od 128 trudnica kod kojih je postavljena sumnja na poreme}aj metabolizma gluko-
ze. Logisti~kom regresijskom analizom je ispitan odnos razina glukoze nata{te, obiteljske optere}enosti dijabetesom,
indeksa tjelesne mase, maj~inog dobitka na te`ini tijekom trudno}e, poro|ajne te`ine ~eda, njegovog opsega glave i
Apgar zbira izme|u skupina sa i bez GDM. Utvr|eno je kako su razine glukoze nata{te ve}e od 7,0 mmol/L i pretjerana
uhranjenost majke sna`ni prediktori GDM i makrosomije. Usporedba skupina po prisutnosti GDM-a isklju~ila je posto-
janje zna~ajnih razlika prema vrsti poro|aja, te vitalnosti i metaboli~kim komplikacijama novoro|en~adi. Pravodobno
otkrivanje sklonosti poreme}aju metabolizma glukoze u trudno}i i poduzimanje mjera za prikladnu regulaciju glike-
mije, presudni su za spre~avanje nastanka GDM i smanjenje u~estalosti novoro|ena~ke makrosomije. Za postizanje
navedenog cilja, od presudnog je zna~aja sustavno provo|enje mjera edukacije `ena i omogu}avanje stru~ne potpore u
prekoncepcijskoj regulaciji tjelesne te`ine.
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